Voriconazole is used to treat serious fungal infections, including aspergillosis and candidiasis. It works by stopping the growth of fungal organisms that cause these infections.[2] Vfend is currently approved and in use across 25 indications[4].[1]
Vfend is one of 439 small molecule programs targeting Corneal Ulcer. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
2828 competitors in Breast Cancer
Vfend
Tecentriq
Trodelvy
Cymbalta
MS Contin
Lupron
Methylthioninium Chloride
Spravato
Effexor
Nubain
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
May 24, 2002
VFEND
NDA NDA021267
May 24, 2002
VFEND
NDA NDA021266
Dec 19, 2003
VFEND
NDA NDA021630
Mar 9, 2017
VORICONAZOLE
NDA NDA208562
Sources
Details